Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SELB

Selecta Biosciences (SELB) Stock Price, News & Analysis

Selecta Biosciences logo

About Selecta Biosciences Stock (NASDAQ:SELB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.88
$1.26
52-Week Range
N/A
Volume
2.77 million shs
Average Volume
979,585 shs
Market Capitalization
$136.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Stock News Headlines

This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
Cartesian Therapeutics Inc (RNAC)
See More Headlines

SELB Stock Analysis - Frequently Asked Questions

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its quarterly earnings data on Thursday, August, 17th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.05. The business had revenue of $5.25 million for the quarter, compared to analyst estimates of $9.90 million. Selecta Biosciences had a negative net margin of 72.04% and a negative trailing twelve-month return on equity of 44.13%.
Read the conference call transcript
.

Selecta Biosciences (SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Selecta Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), GE Aerospace (GE), Pfizer (PFE), CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/17/2023
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SELB
Employees
64
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$35.38 million
Pretax Margin
-73.23%

Debt

Sales & Book Value

Annual Sales
$110.78 million
Price / Cash Flow
9.91
Book Value
$0.61 per share
Price / Book
N/A

Miscellaneous

Free Float
106,780,000
Market Cap
$136.76 million
Optionable
Optionable
Beta
0.84

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:SELB) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners